Edition:
United Kingdom

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

18.79USD
2:33pm GMT
Change (% chg)

$0.54 (+2.96%)
Prev Close
$18.25
Open
$18.37
Day's High
$18.84
Day's Low
$18.37
Volume
16,026
Avg. Vol
203,489
52-wk High
$24.30
52-wk Low
$11.48

Latest Key Developments (Source: Significant Developments)

Cara Therapeutics Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing
Friday, 15 Mar 2019 

March 15 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $300 MILLION - SEC FILING.  Full Article

Cara Therapeutics posts Q4 Loss Per Share of $0.52
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.52.Q4 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT DECEMBER 31, 2018 TOTALED $182.8 MILLION.$5.5 MILLION OF LICENSE AND MILESTONE REVENUE DURING Q4.CARA THERAPEUTICS - EXPECTS CASH & CASH EQUIVALENTS, AVAILABLE-FOR-SALE MARKETABLE SECURITIES AS OF DECEMBER 31, 2018 SUFFICIENT TO FUND TILL 2021.  Full Article

Cara Therapeutics announces no modifications in trial size after completion of interim statistical assessment for kalm-1 phase 3 trial of Korsuva injection In Hemodialysis Patients With Pruritus
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES NO MODIFICATIONS IN TRIAL SIZE AFTER COMPLETION OF INTERIM STATISTICAL ASSESSMENT FOR KALM-1 PHASE 3 TRIAL OF KORSUVA INJECTION IN HEMODIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS INC - TRIAL CONTINUES AS PLANNED WITH ENROLLMENT TARGET OF 350 PATIENTS.CARA THERAPEUTICS INC - TOP-LINE DATA READOUT FROM TRIAL EXPECTED IN FIRST HALF OF 2019.  Full Article

Cara Therapeutics Reports Q2 Loss Per Share Of $0.52
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.52.Q2 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.Q2 REVENUE $2.9 MILLION.  Full Article

Cara Therapeutics Announces Pricing Of $85.5 Mln Offering Of Common Stock
Thursday, 19 Jul 2018 

July 18 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES PRICING OF $85.5 MILLION OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.50 MILLION COMMON SHARES PRICED AT $19.00PER SHARE.  Full Article

Cara Therapeutics Says Offering 4.50 Mln Common Shares
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS OFFERING 4.50 MILLION COMMON SHARES.INTENDS TO USE NET PROCEEDS FROM UNDERWRITTEN OFFERING TO FUND ITS CLINICAL AND RESEARCH DEVELOPMENT ACTIVITIES.  Full Article

Cara Therapeutics Inc reports Q3 loss per share $0.38
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Cara Therapeutics Inc :Cara Therapeutics Inc reports third quarter 2017 financial results.Q3 loss per share $0.38.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Cara Therapeutics Inc - expects existing cash and cash equivalents, among others to be sufficient to fund operating expenses, capex requirements into 2019​.  Full Article